Pyxis Oncology
PYXS
Pyxis Oncology (PYXS) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Aug 18, 2026 |
| Wells Fargo | Initiated Coverage | Overweight | $12.00 | Aug 3, 2026 |
| Leerink Partners | Maintained | Outperform | $7.00 from $9.00 | Jul 2, 2026 |
| Wedbush | Initiated Coverage | Outperform | $6.00 | May 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Mar 24, 2026 |
| Stifel | Maintained | Buy | $8.00 from $9.00 | Mar 24, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 from $5.00 | Dec 19, 2025 |
| RBC Capital | Maintained | Outperform | $5.00 from $8.00 | Dec 19, 2025 |
| Stephens & Co. | Maintained | Overweight | $8.00 from $5.00 | Nov 24, 2025 |
| Guggenheim | Maintained | Buy | $7.00 from $5.00 | Nov 4, 2025 |
| Guggenheim | Initiated Coverage | Buy | $5.00 | Sep 4, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 | Aug 19, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 | May 19, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 | Mar 19, 2025 |
| RBC Capital | Maintained | Outperform | $8.00 | Mar 19, 2025 |
| RBC Capital | Maintained | Outperform | $8.00 from $10.00 | Dec 20, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 from $7.00 | Dec 20, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Nov 21, 2024 |
| William Blair | Downgraded | Outperform → Market Perform | — | Nov 21, 2024 |
| RBC Capital | Maintained | Outperform | $10.00 from $7.00 | Nov 21, 2024 |
Frequently asked questions
What is the latest analyst rating on PYXS?
On Aug 18, 2026, HC Wainwright & Co. maintained Pyxis Oncology at Buy with a price target of $7.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.